iCAD, Inc. (ICAD)

NASDAQ: ICAD · IEX Real-Time Price · USD
1.810
+0.240 (15.29%)
Feb 28, 2024, 3:08 PM EST - Market open
15.29%
Market Cap 41.11M
Revenue (ttm) 22.21M
Net Income (ttm) -10.00M
Shares Out 26.35M
EPS (ttm) -0.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 759,390
Open 1.560
Previous Close 1.570
Day's Range 1.560 - 1.915
52-Week Range 1.050 - 3.970
Beta 1.28
Analysts Strong Buy
Price Target 4.00 (+120.99%)
Earnings Date Mar 12, 2024

About ICAD

iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company's breast AI suite includes cancer detection, automated density assessment, and breast cancer risk assessment solutions for both 2D and 3D mammography. It offers PowerLook, a back-end architecture platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a ma... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Dec 3, 1986
Employees 108
Stock Exchange NASDAQ
Ticker Symbol ICAD
Full Company Profile

Financial Performance

In 2022, iCAD, Inc.'s revenue was $27.94 million, a decrease of -16.93% compared to the previous year's $33.64 million. Losses were -$13.66 million, 21.4% more than in 2021.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ICAD stock is "Strong Buy." The 12-month stock price forecast is $4.0, which is an increase of 120.99% from the latest price.

Price Target
$4.0
(120.99% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings

NASHUA, N.H., Feb. 28, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect canc...

7 hours ago - GlobeNewsWire

iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)

Dr. Hricak offers extensive experience in radiology, real-world application of AI-enabled imaging solutions, research, and global healthcare perspectives Dr. Hricak offers extensive experience in radi...

1 day ago - GlobeNewsWire

iCAD to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

NASHUA, N.H., Feb. 27, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect canc...

1 day ago - GlobeNewsWire

iCAD's AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare

NASHUA, N.H., Nov. 28, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, today announced that key artificial intelligence...

3 months ago - GlobeNewsWire

iCAD's ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease

New research presented at Radiological Society of North America annual meeting confirms ability of ProFound Breast Health Suite to predict a woman's one to two-year risk for breast cancer iCAD unveils...

3 months ago - GlobeNewsWire

iCAD to Participate in the 14th Annual Craig-Hallum Alpha Select Conference

NASHUA, N.H., Nov. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health...

3 months ago - GlobeNewsWire

iCAD Reports Financial Results for Third Quarter Ended September 30, 2023

NASHUA, N.H., Nov. 13, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health...

3 months ago - GlobeNewsWire

iCAD to Report Third Quarter 2023 Financial Results on November 13, 2023

NASHUA, N.H., Oct. 30, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast hea...

4 months ago - GlobeNewsWire

iCAD, Inc. Announces Sale of Xoft, its Brachytherapy Business Line, to Elekta

Xoft's eBx System can now be offered to more clinics and cancer patients world-wide through Elekta's extensive sales channels Xoft's eBx System can now be offered to more clinics and cancer patients w...

4 months ago - GlobeNewsWire

Health Canada Grants Device License for iCAD's ProFound Risk 2.0, Revolutionizing Breast Cancer Risk Via a 1-2 Year Assessment

NASHUA, N.H., Aug. 16, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Health Canada...

7 months ago - GlobeNewsWire

iCAD Reports Financial Results for Second Quarter Ended June 30, 2023

NASHUA, N.H., Aug. 14, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial ...

7 months ago - GlobeNewsWire

iCAD to Report Second Quarter 2023 Financial Results on August 14, 2023

NASHUA, N.H., July 31, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will relea...

7 months ago - GlobeNewsWire

iCAD Signs Strategic Commercial Agreement with Radiology Partners, the Nation's Largest Radiology Practice

Agreement positions iCAD as Radiology Partners' breast AI provider, expanding potential for iCAD's technology to reach millions of women in the U.S. Agreement positions iCAD as Radiology Partners' bre...

8 months ago - GlobeNewsWire

iCAD's “ProFound Insights, ProFound Impact” Webinar Series to Feature Cleveland Clinic

Cleveland Clinic breast radiologist, Laura Dean, MD, to discuss how iCAD's Breast AI Suite helps her detect the breast cancers radiologists fear most Cleveland Clinic breast radiologist, Laura Dean, M...

8 months ago - GlobeNewsWire

iCAD Offers ROI Analysis Based on Real-World Results from its ProFound Breast AI Suite at AHRA Annual Meeting

Company's ROI Tool offers preview of business value the ProFound Breast AI Suite offers to clinicians and imaging facilities Company's ROI Tool offers preview of business value the ProFound Breast AI ...

8 months ago - GlobeNewsWire

iCAD's ProFound AI Breast Suite Wins U.S. General Services Administration's AI Healthcare Challenge Award

Company presented portfolio of breast cancer detection, density assessment and risk evaluation solutions at the competition, focused on improving health outcomes Company presented portfolio of breast ...

10 months ago - GlobeNewsWire

iCAD Reports Financial Results for First Quarter Ended March 31, 2023

NASHUA, N.H., May 15, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial a...

10 months ago - GlobeNewsWire

ProFound AI Risk Outperforms Traditional, Widely-Accepted Breast Cancer Risk Models for Both Short-term and Long-term Risk Assessments

ProFound AI Risk offered higher accuracy than Tyrer-Cuzick v8 for all women, regardless of menopausal status, breast density, and family history of breast cancer ProFound AI Risk offered higher accura...

11 months ago - GlobeNewsWire

iCAD Reports Financial Results for Fourth Quarter ended December 31, 2022 and Year End

Strategy focused on profitability by end of 2024, using current cash on hand

1 year ago - GlobeNewsWire

iCAD's Breast AI Suite Empowers Customers to Lead the Way in Support of FDA's National Breast Density Reporting Standard

iCAD showcases Breast AI Suite at National Consortium of Breast Centers (NCoBC) 32nd Annual Conference iCAD showcases Breast AI Suite at National Consortium of Breast Centers (NCoBC) 32nd Annual Confe...

1 year ago - GlobeNewsWire

iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023

Company is exploring strategic options for its Therapy business line Company is exploring strategic options for its Therapy business line

1 year ago - GlobeNewsWire

New Real-World Clinical Evidence Confirms ProFound AI Boosts Radiologists' Efficiency and Accuracy

Company's Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools showcased at ECR 2023 Company's Breast AI Suite of deep-learning breast cancer detectio...

1 year ago - GlobeNewsWire

iCAD Announces CFO Transition and Hires New Senior Vice President, US Commercial Sales, AI

Daniel Shea appointed as interim Chief Financial Officer

1 year ago - GlobeNewsWire

iCAD features Solis Mammography in upcoming “ProFound Insights, ProFound Impact” webinar

Solis Mammography's Chief Medical Officer Chirag Parghi, MD, to share clinical experience and real-world case studies demonstrating clinical value of ProFound AI Solis Mammography's Chief Medical Offi...

1 year ago - GlobeNewsWire

Positive New Research Presented at RSNA 2022 Reaffirms iCAD's Breast AI Suite Improves Radiologists' Performance and Breast Cancer Detection

Study affirms utility of ProFound AI's Case Scores in improving cancer detection

1 year ago - GlobeNewsWire